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Summary Increased Plasmodium falciparum resistance to chloroquine has prompted national
malaria programs to develop new policies in several African countries. Less than a year after
the introduction of amodiaquine/sulfadoxine—pyrimethamine (AQ/SP) as ﬁrst-line treatment
in Senegal, we examined adherence rates to therapy and its efﬁcacy among children. The study
was conducted in ﬁve dispensaries in rural Senegal. Children aged 2—10 years with a presumptive
diagnosis of malaria were prescribed AQ/SP. Thick blood ﬁlm analyses were carried out on days
0, 3, 7, 14 and 28. Blood and urine samples were collected on day 3 for drug level measurements.
The principal caregivers were questioned on treatment adherence. Among the 289 recruited
children, 144 had a parasitemia >2500/l. The results demonstrated markedly good efﬁcacy
for the treatment, as no detectable parasitemia was observed on day 28 for 97.9% of the
children. However, we noticed that 35.3% of children did not comply with the recommended
doses and 62.3% did not exactly adhere to the drug schedule. Despite the good efﬁcacy of the
drugs, adherence to the therapeutic scheme was poor. Strategies to promote patient adherence
would improve drug performance and thus might help to prevent the rapid emergence of drug
resistance.
opica© 2008 Royal Society of Tr
reserved.∗ Corresponding author. Tel.: +33 1 53731507; fax: +33 1 53739617.
E-mail address: souares@uni-heidelberg.de (A. Souares).
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. Introductionach year, malaria is responsible for 300 to 500million new
ases worldwide and accounts for 1 to 2million deaths, pre-
ominantly among young children in Africa. For decades,
hloroquine (CQ) was used as ﬁrst-line treatment. High drug
e and Hygiene. Published by Elsevier Ltd. All rights reserved.
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ressure through self-medication, poor treatment adher-
nce and under-utilization of health facilities has caused CQ
esistance in many sub-Saharan countries (Nuwaha, 2001).
his resistance led to an increase in mortality and morbid-
ty and prompted national malaria programs to develop new
olicies in most African countries. Combination therapy with
ntimalarial drugs that have different modes of action has
een shown to improve the treatment efﬁcacy of individ-
al drugs (WHO, 2001) and decrease the risk of resistance.
he introduction of artemisinin-based combination therapy
ACT) has been shown to increase cure rates (White, 1999)
nd has been ofﬁcially recommended by WHO (2001).
Nearly all high-burden African countries have seen an
nprecedented change in national drug policies in recent
ears. In line with the WHO recommendations, they gave
p CQ, which had become ineffective, to promote ACT as
rst-line treatment for mild malaria. If this implementa-
ion is ofﬁcial in most of the countries, there are still a
arge proportion of countries in which the combinations are
ot available in health facilities and children are treated
ith less effective monotherapies. Data available between
004 and 2006 in 14 countries supposedly already using ACT
howed that in reality it has been used for less than 6% of
ebrile children (UNICEF, 2007). Moreover, there is little evi-
ence concerning adherence to ACT and other therapeutic
ombinations to date. The new therapy may be subject to
he same pressures and might suffer a setback similar to that
f CQ (White, 2004).
Before a broad utilization of ACT becomes successful
hroughout the African continent, several issues need to
e addressed (Bloland et al., 2000), particularly that of
atient treatment adherence: the degree to which a patient
dheres to the prescribed treatment schedule. Poor patient
dherence has serious consequences in terms of drug effec-
iveness. It is likely to be lower for patients who do not
omplete their treatment (Yeung and White, 2005).
Faced with an average CQ treatment failure of 25% (Gaye,
002), Senegal changed its national malaria treatment pol-
cy from CQ to amodiaquine/sulfadoxine—pyrimethamine
AQ/SP) in 2003. In 2006, they shifted to ACT. The intro-
uction of this combination therapy can be considered a
est before the implementation of ACT in terms of health
taff behavior and public adherence to new drugs and drug
ombinations.
Less than a year after the introduction of AQ/SP as ﬁrst-
ine treatment in Senegal, this study was undertaken to
xamine patient adherence rates and drug effectiveness
mong children.
. Materials and methods
.1. Study area and population
he study was conducted in the rural areas of Mbour and
hies: two departments situated about 90 km southeast of
akar, capital city of Senegal. The population in this region is
ainly Sereer. Millet and groundnuts are the principal tradi-
ional staple crop and cash crop, respectively. The farmers in
his area also raise cattle. To cope with the agricultural cri-
is, new activities have arisen, such as temporary migration
o urban centers, particularly to Mbour and tourist areas.
a
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Malaria is endemic in this area, with seasonal outbreaks.
he annual rainy season is short (July—October). Malaria
ransmission is mainly restricted to the months from August
o November. The study took place in 2004 during the rainy
eason. We chose ﬁve health centers that are represen-
ative of health-care provision in rural Senegal (staff and
echnical means, population scattering around the health
enters, recruitment area). Urban and tourist areas and
ealth centers with special non-governmental organization
ealth interventions were avoided. A homogeneous geo-
raphic area representing 30 037 people was deﬁned.
The selected health centers provide basic services to the
tudy population: curative care, immunization, pre-natal
are, delivery and malnutrition management. The health
tructures are staffed by nurses and birth attendants. There
re no permanent physicians, midwives, laboratory facilities
r emergency transportation. Health centers were selected
n terms of patient attendance in order to obtain the daily
inimum patient recruitment among children.
.2. Design and procedures
uring the study period, nurses identiﬁed all the children,
ged between 2 and 10 years, who presented with fever
axillary temperature >37.5 ◦C) and a presumptive diagnosis
f mild malaria during an initial consultation. A thick blood
lm was done to measure the parasitemia. A urine sample
as collected to evaluate CQ intake before the consultation.
Since the adoption of the new policy, all children are pre-
cribed a single dose of SP (25mg sulfadoxine/kg; 1.25mg
yrimethamine/kg) on day 0 (D0), and one daily dose of AQ
or 3 d (10mg/kg/d) (Table 1). Each provider was given a
hart showing the appropriate dosage by weight and age,
eﬁned by the Senegalese National Malaria Control Program.
he program did not expect nurses to supervise the ﬁrst
ntake. Drugs were available at the health center phar-
acy. No study team member was present at the health
enter. We received the identiﬁcation form from the nurse
nd recruited the children the day after the last treat-
ent dose day 3 (D3), when we visited mothers/guardians at
ome to explain the study and collect their written consent.
part from the study team, no one was aware of this visit
efore our arrival. A questionnaire was administered at D3 to
aregivers and adults who accompanied the children to the
ealth center, with questions related to treatment adher-
nce, history of the febrile illness, knowledge and source of
nformation about antimalarial drugs and awareness of the
ecent policy change.
.3. Effectiveness
or the effectiveness study, thick blood samples were car-
ied out at D0, 3, 7, 14 and 28. In the absence of laboratories
n the health centers, samples were read in the labora-
ory of the French Institute of Research for Development in
bour. Children with Plasmodium falciparum monoinfection
nd parasitemia >2500 parasites/l at D0 were diagnosed
ositively with malaria. Therapeutic outcome was classi-
ed into early treatment failure, late clinical failure, late
arasitological failure or adequate clinical and parasitolog-
cal response (WHO, 2003). Parasites were counted using
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Table 1 Age-speciﬁc dosing schedule for sulfadoxine—pyrimethamine (SP) plus amodiaquine (AQ) in Senegal
Age group Weight (kg) SP tabletsa AQ tabletsb
D0 D0 D1 D2
2—11 months 5—10 0.5 0.5 or 2 tsp 0.5 or 2 tsp 0.5 or 2 tsp
1—2 years 10.1—14 0.75 0.75 or 3 tsp 0.75 or 3 tsp 0.75 or 3 tsp
3—5 years 14.1—20 1 1 or 4 tsp 1 or 4 tsp 1 or 4 tsp
6—8 years 20.1—30 1.5 1.5 1.5 1.5
9—11 years 30.1—40 2 2 2 2
12—13 years 40.1—50 2.5 2.5 2.5 2.5
>14 years >50 3 3 3 3
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a SP: one tablet contains 500mg sulfadoxine and 25mg pyrimetha
b AQ: one tablet contains 153mg amodiaquine and one teaspoon
Giemsa-stained thick blood ﬁlms and parasite density was
calculated based on an assumedmean white blood cell count
of 8000/l. All thick blood ﬁlms were read twice. A slide was
declared negative after 200 negative microscopic ﬁelds. The
pre-treatment of CQ was assessed with urine samples at D0
with the Haskins and Mount, or HMM II, method using methyl
orange (Mount et al., 1989).
2.4. Deﬁnition of adherence
To measure adherence, we compared the caregivers’ admin-
istration of the drugs with the nurses’ prescription. We
deﬁned two indicators of adherence. Firstly, we consid-
ered those who took 80% of the prescribed dose of the two
drugs to be adherent (Dahan et al., 1985). We totaled the
entire drug intake declared and compared the total dose
with the total dose prescribed by the nurse. Secondly, strict
full adherence (SFA) described a patient as fully adherent
to the prescription, including dose, duration and frequency.
Patients were required to take the exact daily dose of AQ
prescribed for 3 d and the exact dose of SP prescribed on
the ﬁrst day. In the case of syrup, the drug providers gave
caregivers the instructions to take 2, 3 or 4 teaspoonfuls a
day. We considered a teaspoonful to hold 5ml.
2.5. Data analysis
Questionnaire data were entered in Dbase and analyzed
using Stata 8 (Stata Corp., College Station, TX, USA). Sam-
ple characteristics and patient classiﬁcation were described
as proportions. Free and informed consent was sought from
the children’s caregivers before administration of the ques-
tionnaires and blood samples.
3. Results
3.1. PopulationOf the 304 patients aged 2—10 years considered by the nurse
to have mild malaria, 289 were included in the study. The
remaining 15 were prescribed quinine by the nurse. One
hundred and forty-four children had laboratory-conﬁrmed
malaria (parasitemia >2500/l) and 145 were diagnosed
3
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= 5ml) contains 50mg amodiaquine.
resumptively by the nurse (117 were negative and 28 had
parasitemia ≤2500/l). The median age of the recruited
hildren was 5.4 years. The sex ratio (male/female) was 1.3.
he mother was the caregiver in 69.5% of cases, followed
y the grandmother (13.2%), the father (7.6%) and others
9.7%). Over 66% of the children had a history of fever in the
revious 24 h, and 54.3% had an axillary temperature over
7.5 ◦C at the time of consultation (Table 2). The urine test
esults showed that 6% of the children took CQ before the
onsultation at the health center.
To compare compliance data from the questionnaire with
lood drug level, we collected blood samples at D3 from
hildren who had a parasite density >2500/l at D0. Sulfa-
oxine and pyrimethamine concentrations were determined
n whole blood using the SPE-HPLC method from the blood
ample taken at D3 (Pussard et al., 1986).
All children were prescribed either SP and AQ (70.6%)
ablets or syrup (29.4%). Nearly all (92.1%) were prescribed
n antipyretic (80.7% aspirin and 11.4% paracetamol); 27%
ere prescribed a fourth drug; and 4.8% were prescribed a
fth drug, usually an antibiotic or antiparasite medication.
Fourteen caregivers (5.9%) did not buy all the drugs pre-
cribed: two of them (0.7%) did not buy AQ; six (2.1%) did
ot buy SP; eight (2.8%) did not buy an antipyretic; and six
2.1%) did not buy another drug.
The mean cost of the prescription is approximately
77 CFA (225—1650) (D 0.88 [0.34—2.52]) and is more expen-
ive for young children, aged 2—4 years (711 CFA =D 1.08),
han for older children, aged 8—10 years (453 CFA =D 0.69),
ecause of the price of the syrup.
.2. Adherence
reatment adherence was measured for all 289 children.
our (1.4%) caregivers said they did not give AQ, and 17 said
hey did not give SP (5.9%). Seventeen children (5.9%) did
ot take one of the two drugs. Four (1.4%) took neither AQ
or SP..2.1. Daily dosage
he daily dosage administered for AQ varied: 60.2% adminis-
ered the correct dosage each day; 12.8% overdosed it; 2.8%
nderdosed it; and 24.2% administered different dosages
both under- and overdosing) over the 3 d period. For SP on
754 A. Souares et al.
Table 2 Main characteristics of the study subjects
Nurses’ clinical diagnosis of malaria
with positive blood ﬁlm
Nurses’ clinical diagnosis of malaria
with negative blood ﬁlm
No. individuals 144 145
No. females (%) 61 (42.3) 64 (44.1)
Mother as caretaker (%) 102 (70.8) 99 (68.2)
Caretaker with no formal education 131 (91) 109 (75.2)
No. children of the caregiver (mean) 4.7 5.1
Median age (year, range) 5.5 (1—10) 5.3 (2—12)
Median weight (kg, range) 16.5 (7—30) 16.1 (8—38)
Mean temperature (◦C, range) 38.2 (36.5—40.9) 38 (36.3—40.5)
Geometric parasitic density (/l, range) 96 365 (2547—1 045 333) 637 (14—1546)
Reported or observed symptoms
Axillary temperature >37.5 ◦C (%) 79 (54.9) 78 (53.8)
History of fever (%) 83 (57.6) 109 (75.2)
Headache (%) 45 (31.2) 58 (40)
Cough (%) 13 (9) 23 (15.9)
Abdominal pain (%) 13 (9) 14 (9.6)
Vomiting (%) 9 (6.6) 16 (12.1)
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(66.5% for tablets and 52.9% for syrup); 28.7% received a
lower dose than prescribed (27.5% for tablets and 32.9% for
syrup); and 9.7% received a higher dose (6% for tablets and
14.2% for syrup). For SP, 67.5% took the correct dose, while
9.3% had underdosed and 23.2% had overdosed.Diarrhea (%) 1 (0.7)
Anemia (%) 7 (4.8)
he ﬁrst day, 65.4% took the correct dose, while 14.2% took
ess and 16.9% took more than was prescribed (Figure 1).
.2.2. Treatment duration
total of 63.5% of caregivers administered AQ for exactly
d and 15.1% continued to give it after the third day. Slightly
ore than 21% did not follow the prescribed regimen of
hree doses of AQ and omitted one (17.9%) or two (3.5%)
oses. At D2, 16.3% did not administer AQ. Approximately
2% did not administer SP as one dose and instead divided
t over 2 or 3 d. Just over three percent (3.3%) of caregivers
aid they had given SP after the third day and 2.8% of the
aregivers did not administer it on the ﬁrst day but did on
he other days (Figure 2)..2.3. Frequency of daily administration
lthough all caregivers were supposed to give the medica-
ion once a day, there was variation in the frequency of
dministration. Approximately 63.7% administered it once
igure 1 Adherence detailed for each intake. AQ: amodi-
quine; SP: sulfadoxine—pyrimethamine.
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day, about 6.2% administered it twice a day (15.3% for
yrup); 0.7% administered it three times a day; and 29.4%
dministered it a varied number of times over the 3 d period.
small percentage (1.5%) administered SP two or three
imes a day.
.2.4. Total dose administered
early 62% of children took the exact prescribed dose of AQigure 2 Adherence to the combination amodiaquine/
ulfadoxine—pyrimethamine (AQ/SP). Intake: administration
f the drug at least one time; 80% adherence: administration
f 80% of the prescribed dose; correct duration: administration
f the drugs 1 d for SP and 3 d for AQ; correct frequency of daily
dministration: administration of one dose a day; correct daily
osage: administration of the correct dosage for each intake;
trict full adherence: administration exactly as prescribed by
he nurse (dose, duration, frequency).
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3.2.5. Treatment adherence measurement: 80%
adherent and SFA
Numerous studies examining acute episodes of the disease
considered patients to be adherent if they took 80% of the
prescribed dose. Accordingly, 209 (72.3%) were adherent to
AQ and 245 (84.8%) to SP. Hence, a total of 187 caregivers
(64.7%) were adherent to both drugs. However, only 39.4%
of caregivers demonstrated SFA for AQ and 60.9% did so for
SP. Adherence to treatment with tablets was better than
with syrup (45% compared with 28.2%, respectively). Over-
all, 37.7% of the caregivers strictly followed the prescription
for the two drugs (Figure 2).
3.3. Biological measure and declarative measure
Only the children who had a positive parasitemia were
included in this part of the study. We considered qualitative
results — absence or presence — for HPLC. There is good sim-
ilarity (90%) between interview and HPLC. When comparing
interviews with blood concentration, seven (5%) caregivers
said they had given SP to their children and HPLC dosage
was negative; and seven (5%) said they had not given SP and
the children were positive.
3.4. Effectiveness
All the children with positive parasitemia (144/289) received
clinical and parasitological follow-up for 7 d and 97.9%
(141/144) received the follow-up for 28 d. The effective-
ness of the treatment was markedly good. No detectable
parasitemia was observed at D3 for 87.6% of the chil-
dren. Among those who were positive, parasitemia rates
were low (480/l), except for two subjects who had
high rates (>2500/l). We observed one early thera-
peutic failure; one child remained positive during the
entire follow-up but without any clinical signs. This child
was classiﬁed as non-observant, as his parents bought
the drugs but they did not administer it because he
felt better. At D28, 97.9% of the children had a nega-
tive thick blood ﬁlm. We observed two late therapeutic
failures: two children became positive again at D28
(Figure 3).
Figure 3 Effectiveness of combination therapy. Effective-
ness was measured for all laboratory-conﬁrmed malaria cases
(n = 144).
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.5. Drug perceptions and instructions concerning
he medication
ll interviewed caregivers and accompanying adults stated
hat they were not aware of malaria treatment policy
hanges. Families were unaware of the concept of associa-
ion: the use of two drugs to treat one disease. AQ was linked
o CQ due to its bitterness and the shape of the tablets. SP
as not associated with malaria treatment; the caregivers
istook it for an antipyretic because of its similarity in color
white) and size.
The treatment was perceived as difﬁcult to administer
o the children by 10.4% of the caregivers, as children cried
29.1%) or refused to take the tablets. Slightly over 26%
f the children vomited when the drug was administered
r itched after taking the medication. Symptoms played an
mportant role in treatment adherence. For example, 20.1%
hought it was unnecessary to continue the treatment if
heir child no longer appeared sick. The majority (90.3%)
f the caregivers said that they were not provided with
nformation concerning the prescribed drugs at the time
f consultation. Most of them (72.3%) had been provided
ith information by the pharmacist; however, 68% of them
eported that the information on drug intake was inade-
uate.
. Discussion
igh drug pressure through self-medication, poor adherence
nd under-dosage has led to CQ resistance and frequent
herapeutic failures (Basco, 2004; McCombie, 1996). In
004, Senegal changed its antimalarial strategy for AQ/SP
n order to tackle this resistance. Our study aimed to ana-
yze population adherence to the new strategies for treating
alaria.
.1. Treatment adherence to the AQ/SP
ombination
ew studies are available on antimalarial combination ther-
py adherence, and the lack of a uniform methodology
akes true comparison difﬁcult (Yeung and White, 2005). A
ide range of deﬁnitions concerning adherence are typically
sed. Additionally, only a small proportion of the studies
sed detailed deﬁnitions of adherence that included doses,
uration and frequency (Ansah et al., 2001; Depoortere et
l., 2004; Yepez et al., 2000). This detailed deﬁnition is more
peciﬁc but also more complex and requires reconstruction
f the entire drug-intake history. For this study we used two
reatment adherence indicators. First, we used a deﬁnition
f 80% adherence, signifying that caregivers had given more
han 80% of the prescribed dose to their children (Dahan et
l., 1985). We also used a very precise deﬁnition, called SFA.
nly those patients who took all the prescribed medication
or the correct number of days and at the correct dosage
ach day were classiﬁed as strictly adherent.
We compared our results from both indicators to results
rom other studies. If we considered only the intake quan-
ity, adherence at the 80% level was weaker in our study
64.7%) than that described by Fogg et al. (2004) in Uganda
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91%), where a new drug combination was tested, or by
nsah et al. (2001) in Ghana (90%), where new CQ pack-
ging was introduced. Our results were more closely related
o the Reilley study in Sri Lanka, where 74% of patients
ere adherent when only total medication intake was con-
idered (Reilley et al., 2002). The large differences might be
xplained by particular study conditions; for example, new
rugs or new packaging tests (Ansah et al., 2001; Fogg et al.,
004). In these studies, the use of written consent at D0 and
aregiver training induced differences in the usual health
ractices and may have had an impact on patient behav-
or, as people were aware of the research before treatment
ad commenced (Osterberg and Blaschke, 2005). We tried to
easure adherence while limiting similar biases as much as
ossible. We did not modify any of the health center’s oper-
tions; no team member was present at the health center,
nd patients knew about the study only once the treatment
ad supposedly ﬁnished.
Only 37.7% of patients were adherent in this study if we
sed the deﬁnition of SFA. Depoortere et al. (2004), using
he same indicator, found that 39% of patients were compli-
nt to a 3 d regimen of AS/SP. Adherence concerns not only
edication intake but also treatment duration, dosage and
requency of administration. The SFA permits us to take into
ccount all of these components.
.2. Measures of adherence
ome previous studies have shown that caregivers or self-
eported drug histories were subject to biases and errors
nd are thus not reliable (Nwanyanwu et al., 1996) and
ould need to be validated by drug concentration (Yeung
nd White, 2005). Our data collection required a long
nd detailed caregiver interview and allowed us to obtain
eliable data for biological assessment. Blood drug assays
ere carried out in our study and we obtained good
greement between the questionnaire and blood concen-
ration of the drugs. However, it was not possible to
ighlight the link between dose intake and blood drug level
or each compound. Blood drug concentrations cannot be
ranslated into a strong estimate of adherence, because
evels vary considerably between individuals, depending
n a variety of uptake, metabolic and elimination fac-
ors (Souares, unpublished data). The same conclusion was
eported in Uganda with artemether—lumefantrine (Fogg
t al., 2004). The differences between stated behavior
nd blood sample have been investigated and might be
xplained by confusion between SP and antipyretics; SP
ablets were mistaken for antipyretics because of their
hape (they are a little bigger) and their white color.
aregivers may have confused them and did not realize
hat they took two different drugs. Other authors also
howed that the reported behavior has an advantage over
lood levels in determining how the drug was administered
Kofoed et al., 2003; Qingjun et al., 1998). Asking patients
on-judgmentally about medication-taking behaviors and
ecreasing the delay between treatment and questionnaire
dministration (D3, in our survey) are practical strate-
ies for identifying poor adherence and reducing possible
rror or distorted information (Osterberg and Blaschke,
005).
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.3. Relation between adherence and
ffectiveness
reatment adherence and effectiveness are closely related;
patient cannot be cured without taking their drugs and
‘drugs don’t work in patients who don’t take them’’
Osterberg and Blaschke, 2005). In our study, despite low
dherence among 35.3% of patients, we found a high rate of
fﬁcacy: 97.9% of the children had a negative parasitemia
t D28.
Sokhna et al. (2001) found that, at D14, the percent-
ges of in vivo resistant infection to AQ or SP were 16 and
%, respectively, for 266 Senegalese children with uncompli-
ated malaria. Thus, this strongly suggests that each drug is
ffective on its own. If caregivers gave their child at least
ne of the two drugs, they were likely to be cured. More-
ver, the drug therapy combination reinforces treatment
ffectiveness. At D28, no therapeutic failure was noted
mong 181 patients who were administered both AQ and
P (Gaye, 2002). In Burkina Faso, Zongo et al. (2005) found
hat this treatment was effective 95.8% of the time, and
ockenhaupt et al. (2005) in Ghana observed an even higher
ate of effectiveness (98%). Similar results were reported
rom Rwanda and Uganda, with 97.7% efﬁcacy at D28 (Dorsey
t al., 2003; Rwagacondo et al., 2003).
Our results also show that 47.7 and 86.1% of patients
sing AQ and SP, respectively, received a dose greater than
he theoretical dose. In interviews, nurses explained they
hoose to overdose children by taking age into account
nstead of weight for underweight children or because of
he particular seriousness of the disease. This problem is
lso linked to the tablets, which are difﬁcult to divide and
annot be adapted to an exact dose corresponding to body
eight. As a result, children may have taken the curative
ose even if they were non-adherent to the prescription.
However, good drug effectiveness, as we observed in our
tudy, could have a negative impact on treatment adher-
nce. One caregiver out of ﬁve omitted at least one dose,
ore often the last one (16.3%). This result corroborates the
ttitudes of the family: they declared they did not give the
ablets to the child after the symptoms stopped. In Ecuador,
epez noticed among others factors that ‘‘getting cured
uickly’’ also did not help adherence (Yepez et al., 2000).
.4. Barriers to adherence and potential for ACT
mplementation
ata collected on adherence to AQ/SP combinations inform
s about problems that might be encountered with ACT.
owever, while AQ/SP were separated, the ACT, at least
or the two main combinations artesunate/amodiaquine
AS/AQ) and artemether/lumefantrine (AL), are available
n a single blister pack integrating both molecules. This
s expected to simplify the drug intake and validate the
oncept of association in people’s minds. But before a co-
ormulation, such as Coarsucam, is available worldwide,
he main problem concerns the number of tablets and
ack of pediatric form for one of the two principal com-
inations (AS/AQ). Co-formulation will limit the number
f tablets to take and should thereby promote adher-
nce to treatment. However, even if these elements should
RA
B
B
D
D
D
F
G
K
M
M
M
N
N
OAdherence and effectiveness in malaria treatment
facilitate drug intake, poor adherence to treatment seems
to be principally linked to a lack of understanding. In our
study, caregivers’ interviews revealed the lack of informa-
tion received at the health center. It was shown that detailed
information, notably using pictures and verbal instructions,
could improve adherence from 36.5 to 73.3% in a survey
made in Nigeria (Okonkwo et al., 2001). In particular, fami-
lies need information on the differences between symptoms
and the outcome of the disease. Unfortunately, the nurses
themselves did not receive much information on the new
therapy, which did not help them to inform their patients
and patients’ caregivers (Souares et al., 2006). For a suc-
cessful implementation and utilization of ACT in Africa,
countries should really focus on nurse training and diffu-
sion of information among the population in relation to the
introduction of new drug combinations.
5. Conclusions
Efforts must be made to better understand factors that
might impact compliance and improve it by helping care-
givers to adhere to the prescribed treatment. The provision
of packaging such as pre-packet tablets, co-formulated
treatment therapy or a container with the required volume
and ameasuring spoon for syrup could also have an impact on
mothers’ adherence to recommended doses. Nevertheless,
in the absence of pertinent training for health center staff
and speciﬁc communication to patients and caregivers, new
policy implementations were and will continue to be accom-
panied by misunderstanding and non-adherence. Lessons
from this transitional experience in Senegal would be use-
ful for ACT implementation and should focus the attention
of policymakers on patient and health staff adherence to
treatment. Non-adherence to ACT treatment could result
in an increase in the number of therapeutic failures with
the subsequent emergence of chemoresistance. In the long
term, these different processes could lead to a failure of
this new malaria control strategy.
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